John Mascarenhas, MD, The Mount Sinai Hospital, New York, NY, talks on risk-adapted therapy in essential thrombocythemia (ET) and polycythemia vera (PV), discussing its purpose and how risk is determined, and also comments on emerging data on ropeginterferon alfa-2a and ropeginterferon alfa-2b. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.